Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions

Zhou, Caicun; Tang, Kejing; Chul Cho, Byoung; Liu, Baogang; Paz‐Ares, Luis; Y. Cheng, Susanna; Kitazono, Satoru; Thiagarajan, Muthukkumaran; W. Goldman, Jonathan; K. Sabari, Joshua; E. Sanborn, Rachel; S. Mansfield, Aaron; Hung, Jen‐Yu; Boyer, Michael; Popat, Sanjay; Mourão Dias, Josiane; Felip, Enriqueta; Majem, Margarita; Gümüş, Mahmut; Kim, Sang‐We; Ono, Akira; Xie, John; Bhattacharya, Archan; Agrawal, Trishala; Martin Shreeve, S.; E. Knoblauch, Roland; Park, Keunchil; Girard, Nicolas

doi:10.1056/nejmoa2306441

Public

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Published in New England Journal of Medicine • Oct 21, 2023

Authors:

Caicun Zhou

Kejing Tang

Byoung Chul Cho

Abstract

Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease progression during or after platinum-based chemotherapy. Phase 1 data showed the safety and antitumor acti...

Subject

Epidermal growth factor receptor

Lung cancer

Exon

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!